Investigation of circulating lncRNAs in B-cell neoplasms

Işin, Mustafa; Özgür, Emre; Çetin, Güven; Erten, Nilgün; Aktan, Melih; Gezer, Uğur; Dalay, Nejat

doi:10.1016/j.cca.2014.02.010

Cited by 147 publications

(118 citation statements)

References 49 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…Here, we define mRNA and lncRNA as long RNA. We, and other researchers, have demonstrated that some circulating long RNAs are stable in blood and have diagnostic potential in cancer management (10)(11)(12)(13)(14)(15). The diagnostic value of circulating miRNAs has been intensely investigated (16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer

Dong

Lin

Pan

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

184

111

View full text Add to dashboard Cite

Background: Long noncoding RNA (lncRNA) and mRNAs are long RNAs (!200 nucleotides) compared with miRNAs. In blood, long RNAs may be protected by serum extracellular vesicles, such as apoptotic bodies (AB), microvesicles (MV), and exosomes (EXO). They are potential biomarkers for identifying cancer.Methods: Sera from 76 preoperative colorectal cancer patients, 76 age-and sex-matched healthy subjects, and 20 colorectal adenoma patients without colorectal cancer were collected. We investigated the distribution of long RNAs into the three vesicles. Seventy-nine cancer-related long RNAs were chosen and detected using qPCR.Results: The quantity of long RNA has varying distribution among three subtypes of extracellular vesicles in serum. Most mRNA and lncRNA genes had higher quantity in EXOs than that

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer

Dong

Lin

Pan

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

184

111

View full text Add to dashboard Cite

show abstract

“…The lncRNA was first identified in a genomic scan for genes upregulated in response to taurine treatment in developing mouse retinal cells [77]. TUG1 is upregulated in various human cancers, such as hepatocellular carcinoma, glioma, bladder cancer, esophageal squamous cell carcinoma, gastric cancer, ovarian cancer, renal cell carcinoma [78], but downregulated in non-small cell lung cancer and multiple myeloma [79, 80]. …”

Section: Oncogenic Lncrnas In Osteosarcomamentioning

confidence: 99%

Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets

Dou

Liu

et al. 2017

Cell Physiol Biochem

129

102

View full text Add to dashboard Cite

Osteosarcoma is the most common primary bone malignancy in children and adolescents. Although improvements in therapeutic strategies were achieved, the outcome remains poor for most patients with metastatic or recurrent osteosarcoma. Therefore, it is imperative to identify novel and effective prognostic biomarker and therapeutic targets for the disease. Long noncoding RNAs (lncRNAs) are a novel class of RNA molecules defined as transcripts >200 nucleotides that lack protein coding potential. Many lncRNAs are deregulated in cancer and are important regulators for malignancies. Nine lncRNAs (91H, BCAR4, FGFR3-AS1, HIF2PUT, HOTTIP, HULC, MALAT-1, TUG1, UCA1) are upregulated and considered oncogenic for osteosarcoma. Loc285194 and MEG3 are two lncRNAs downregulated and as tumor suppressor for the disease. Moreover, the expressions of LINC00161 and ODRUL are associated with chemo-resistance of osteosarcoma. The mechanisms for these lncRNAs in regulating development of osteosarcoma are diverse, e.g. ceRNA, Wnt/β-catenin pathway, etc. The lncRNAs identified may serve as potential biomarkers or therapeutic targets for osteosarcoma.

show abstract

“…Previous studies have suggested that MALAT-1 expression in B-cell malignancies is decreased compared with solid tumors (27,69). Another study demonstrated significantly lower MALAT-1 expression levels in the plasma of MM patients (70).…”

Section: Potential Clinical Applications Of Malat-1mentioning

confidence: 94%

Novel insight into MALAT-1 in cancer: Therapeutic targets and clinical applications

Ren

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Long non-protein-coding RNAs (lncRNAs) are emerging as important gene expression regulators that are linked to various biological processes at the post-transcriptional and transcriptional levels. lncRNAs are known to be important in cell proliferation, cell differentiation, apoptosis and metastasis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a novel lncRNA, is highly conserved amongst mammals. In addition, it has been considered to act as an oncogene, depending on the tumor system. An increasing number of studies have indicated that MALAT-1 may be detected in certain types of human tumors, including lung and bladder cancer and hepatocellular carcinoma. MALAT-1 silencing may be an effective therapeutic approach against tumors. The present study reviews the current knowledge on the functional role of MALAT-1 in the control of various cancers.

show abstract

Investigation of circulating lncRNAs in B-cell neoplasms

Cited by 147 publications

References 49 publications

Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer

Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer

Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets

Novel insight into MALAT-1 in cancer: Therapeutic targets and clinical applications

Contact Info

Product

Resources

About